<DOC>
	<DOCNO>NCT00428896</DOCNO>
	<brief_summary>Based preclinical data , ZD1839 consider novel promising therapeutic approach potential application treatment human breast cancer . Therefore could important clinically relevant know ZD1839 capable eliminate occult tumour cell circulate blood breast cancer patient</brief_summary>
	<brief_title>A Feasibility Study With Iressa Resistant Cytokeratin-Positive Tumor Cells Circulating Blood Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision write informed consent Histologically cytologically confirm breast cancer Metastatic breast cancer ( stage IIIB IV ) Patients receive least one course standard systemic chemotherapy metastatic disease . There least one month end chemotherapy treatment trial entry . ER+ve patient receive adjuvant hormonal treatment Detection CK19 mRNA positive cell blood real time PCR despite previous administration chemotherapy appropriate hormonal therapy Aged 18 year Paraffinembedded tissue available tumour histology ( EGFR testing , ER , PgR , Her2neu test ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 Patients willing undergo regular detection circulate occult tumour cell blood immunocytochemistry and/or RTPCR Life expectancy least 12 week Any concurrent systemic treatment breast cancer ( include chemotherapy , radiotherapy , hormonotherapy , monoclonal antibody ) Known severe hypersensitivity ZD1839 excipients product Any evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic need exclude ) Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Any unresolved chronic toxicity great common toxicity criterion ( CTC ) grade 2 previous anticancer therapy ( except alopecia ) Serum bilirubin great 1.5 time upper limit reference range ( ULRR ) As judge investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) great 3 time ULRR . Evidence significant clinical disorder laboratory find make undesirable subject participate study Pregnancy breast feeding ( woman childbearing potential ) . Women childbearing potential must practice acceptable method birth control prevent pregnancy Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort Treatment nonapproved investigational drug within 30 day Day 1 study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>iressa circulate tumor cell</keyword>
</DOC>